Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

January 2, 2020 updated by: Hosam Mohammad Ahmad, Minia University

Study of Using Serum Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus

The aim of this study is to assess the significance of serum fetuin-A as a marker of obesity and type 2 diabetes mellitus. We used multiple statistical approaches to determine that the fetuin-A level is correlated to body mass index (BMI) as well as random blood sugar in type 2 diabetic patients. Also, we found that there is a Positive correlation between the serum fetuin-A levels and the level of glycosylated hemoglobin (HbA1c) in diabetic patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study was a case-control study. We started the study to be performed on eighty subjects divided into four groups:

The first group: include twenty subjects with type 2 diabetes mellitus The second group: include twenty obese subjects whose body mass index is 30 or over The third group: include twenty obese subjects with type 2 diabetes mellitus The fourth group includes twenty apparently healthy subjects as control.

In this study, we concluded that:

  1. Serum fetuin-A can be used as a biomarker and independent risk factor and marker for diagnosis of DM and DM has a detrimental effect on serum fetuin-A fetuin-A could be of relevance for the development of insulin resistance
  2. Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance
  3. Increased serum fetuin-A levels constitute an independent marker of lipid profile.
  4. fetuin-A may play a role in the pathogenesis of T2DM.
  5. The inhibition of insulin receptor by fetuin-A may lead to increased lipolysis and efflux of free fatty acids from adipose tissue. This could explain associated dyslipidemia observed in type 2 diabetic patients in the present study.

Finally, our finding that high plasma fetuin-A levels predict the incidence of type 2 diabetes independently of other established risk factors supports the hypothesis that fetuin-A may play a role in the development of type 2 diabetes.

Study Type

Observational

Enrollment (Actual)

400

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 60 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Description

Inclusion Criteria:

  • • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Exclusion Criteria:

  • • Cardiac disease and Hypertensive disease

    • Respiratory disease
    • Renal disease
    • GIT and Liver disease
    • Rheumatologic disease
    • Blood disease
    • Endocrine disease except for type 2 diabetes mellitus
    • All with a specific therapeutic drug history.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The first group
Include One hundred patients with type 2 diabetes mellitus with average body mass index.
Diagnostic test: Serum Level Of Fetuin A
The second group
Include One hundred patients whose body mass index is 30 or over without diabetes.
Diagnostic test: Serum Level Of Fetuin A
The third group
Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
Diagnostic test: Serum Level Of Fetuin A
The fourth group
Include One hundred apparently healthy adult person as a control.
Diagnostic test: Serum Level Of Fetuin A

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1- Study of human serum fetuin-A and whether it is involved in insulin resistance
Time Frame: Baesline
2- To assess the significance of serum fetuin-A as a marker in obesity and type 2 diabetes mellitus
Baesline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Minia University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

January 2, 2020

First Submitted That Met QC Criteria

January 2, 2020

First Posted (Actual)

January 6, 2020

Study Record Updates

Last Update Posted (Actual)

January 6, 2020

Last Update Submitted That Met QC Criteria

January 2, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • fetuin-A as a marker

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabete Type 2

Clinical Trials on Serum Level Of Fetuin A

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe